SOURCE: Active Motif

February 09, 2007 04:00 ET

Translational Genomics Research Institute (TGen) Licenses AKS2 From Active Motif

CARLSBAD, CA -- (MARKET WIRE) -- February 9, 2007 -- Active Motif today announced that Translational Genomics Research Institute (TGen), based in Phoenix, Arizona, has licensed its unique knowledge mining software, AKS2 (almaKnowledgeServer™). TGen will use this software to facilitate the interrogation of genomic-profiling data such as high-throughput siRNA screening.

"AKS2 will help us integrate prior knowledge located in the literature in a rapid and efficient manner. We will use AKS2 as an integral part of the knowledge mining activities that support the pharmacogenomic-based research activities within TGen," said Dr. Jeff Kiefer, Head of the Knowledge Mining Lab in TGen's Pharmaceutical Genomics Division.

Joseph Fernandez, CEO of Active Motif, commented, "Our customers continue to see the value of biocomputing and knowledge mining tools, and they understand how using these technologies to analyze their data more thoroughly will greatly enhance their research efforts. I am pleased that an organization as prestigious as TGen has selected Active Motif to be an integral part of their pharmacogenomic-based research."

About Active Motif, Inc.

Active Motif, founded in 1999, offers research kits, assays, Chromeon ™ fluorescent dyes, and TimeLogic® biocomputing systems to enable scientists to explore the relationships between genes, proteins and metabolic pathways. Active Motif is located in Carlsbad, California, and has international offices in Tokyo, Japan; Brussels, Belgium; and Regensburg, Germany. Press contact: Darryl León, AKS Product Manager, Active Motif, Inc. tel. 760-431-1263 ext. 223, email: leon@activemotif.com, web site: http://www.activemotif.com.

About TGen

The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research. Press contact: Galen Perry, TGen Communications Director. 602.343.8423 or gperry@tgen.org.

Contact Information